If there is one company that could come onto the radars of investors this morning in a big way, then it is Nordicus Partners Corp. (OTC: NORD). The company was in focus yesterday after significant news emerged with regards to its subsidiary company, Orocidin A/S. The announcement was with regards to the development of a new pathbreaking product.
Dental Gel
In the news release, the Nordicus Partners Corp announced that it had been successful in the development of a unique, pathbreaking, and proprietary dental gel that would be seen as a major product to emerge in the periodontitis treatment space. The gel, which is of low viscosity, features a unique active ingredient and offers an effective as well as efficient solution to the long-term management of the above-mentioned condition.
The Treatment
The gel would be applied by dentists through a syringe and the flushing cannula so that the treatment is applied to the dental pockets directly. It was also noted in the news release that once the gel gets into contact with the moisture of the mouth cavity, that gel would turn into a semi-solid state. Such a structure would help in the localized release of the active peptide.
Key Quote
“Oricidin’s innovative dental gel represents a significant advancement in the treatment of periodontitis,” said Allan Wehnert, founder and CEO of Orocidin. “By combining cutting-edge science with patient-centered design, we aim to improve both outcomes and the overall dental care experience.”.
